Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Diffuse Intrinsic Pontine Glioma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Temozolomide 3Radiotherapy 3TIC10 compound 2Everolimus 2spartalizumab 1ribociclib 1olutasidenib 1lutetium Lu 177 dotatate 1lorlatinib 1larotrectinib 1etoposide phosphate 1balstilimab 1Vaccines 1Standard of Care 1Specimen Handling 1Proto-Oncogene Proteins c-akt 1Phosphatidylinositol 3-Kinases 1Ipilimumab 1Injections 1Immune Checkpoint Inhibitors 1GDC-0084 1Fluid Therapy 1Etoposide 1Eflornithine 1Diphtheria-Tetanus Vaccine 1Cetuximab 1CBLC137 1Biopsy 1Bevacizumab 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Diffuse Intrinsic Pontine Glioma × Fluid Therapy × Clear all
NCT04870944 2026-05-05

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Children's Oncology Group

Phase 1/2 Recruiting
63 enrolled
CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡